Novel PET agent [68Ga]Ga-DPI-4452 shows promise in renal cell carcinoma

The novel agent [68Ga]Ga-DPI-4452 (Debio 0328) provided “outstanding imaging” in patients with clear cell renal cell carcinoma (ccRCC), according to findings from a first-in-human phase 1/2 GaLuCi study (NCT05706129) published in The Journal of Nuclear Medicine.1,2 High-quality imaging with [68Ga]Ga-DPI-4452, a carbonic anhydrase IX (CAIX)-targeting radiolabeled peptide, was observed by researchers as early as 15 minutes after administration, and tumor uptake of [68Ga]Ga-DPI-4452 continued up to 4 hours later. There were only low doses of [68Ga]Ga-DPI-4452 absorbed in the kidney, …